No Data
No Data
China NT Pharma Shareholders to Vote June 28 on Proposed Share Consolidation
Shareholders of China NT Pharma Group (HKG:1011) will meet June 28 to vote on a proposed 10-for-1 share consolidation and a change in board lot size, a Friday filing with the Hong Kong bourse said. Th
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Tailin Pharmaceuticals plans to implement a share merger based on a “10 in 1” basis
Tailing Pharmaceutical (01011) announced that the board of directors recommended a share consolidation based on the basis of merging the issued and unissued shares with a face value of $0.0000,0008 per 10 shares into a consolidated share of $0.0000008 per share. On the date of this announcement, existing shares were traded on the Stock Exchange with 500 existing shares per lot. After the share merger comes into effect, it is proposed that each trading unit traded on the Stock Exchange be changed from 500 existing shares to 10,000 consolidated shares.
Tailing Pharmaceuticals (01011.HK) proposes to change the trading unit for each lot of “10 in 1” shares to 10,000 shares
Gelonghui, May 14, 丨 Tailing Pharmaceutical (01011.HK) announced that the board of directors proposed a “10 in 1” share merger. Stock consolidation is subject to shareholders' approval at a special shareholders' meeting before it can actually take place. After the share merger comes into effect, it is proposed to change the trading unit for each lot traded on the Stock Exchange from 500 existing shares to 10,000 consolidated shares.
Tailing Pharmaceutical (01011) plans to implement a share merger based on a “10 in 1” basis
Zhitong Finance App News, Tailing Pharmaceutical (01011) announced that the board of directors proposed a share consolidation based on the basis of merging issued and unissued shares with a face value of 0.00000008 US dollars per 10 shares into 1 consolidated share of 0.0000008 US dollars per share. On the date of this announcement, existing shares were traded on the Stock Exchange with 500 existing shares per lot. After the share merger comes into effect, it is proposed to change the trading unit for each lot traded on the Stock Exchange from 500 existing shares to 10,000 consolidated shares.
泰凌醫藥:2023 年報
No Data